Abstract | BACKGROUND: METHODS: A single-institution institutional review board-approved database was reviewed. Inclusion criteria were clinicopathologic diagnosis of IBC and age ≥ 18 years. Stage IV disease was excluded. We collected data on demographics, tumor characteristics including histology and subtype, axillary status, and treatment effect details. RESULTS: Sixty-six patients fulfilled criteria. Mean follow-up was 4.1 years. The AXpCR was 6% for luminal A and luminal B [human epidermal growth factor receptor (HER)2 -] subtypes, and 24% for basal subtype. The AXpCR rate was 64% for HER2-enriched and luminal B (HER2 +) patients. Achievement of AXpCR among these HER2-positive patients was statistically significant (p = 0.0001). There was minimal difference in achieving AXpCR in HER2-overexpressing patients regardless of hormone receptor status (p = 1.000). CONCLUSIONS: Understanding the best patients to select for use of SLNB or targeted lymph node dissection after treatment is evolving. This unique series identified and described the axillary pathologic characteristics of IBC patients following NAC. Further research is needed to confirm that the approach, axillary node clip placement prior to treatment, is feasible and accurate in IBC.
|
Authors | Folasade O Imeokparia, Tasha M Hughes, Lesly A Dossett, Jacqueline S Jeruss, Alfred E Chang, Michael S Sabel |
Journal | Annals of surgical oncology
(Ann Surg Oncol)
Vol. 26
Issue 10
Pg. 3374-3379
(Oct 2019)
ISSN: 1534-4681 [Electronic] United States |
PMID | 31342381
(Publication Type: Clinical Trial, Journal Article)
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Axilla
- Female
- Follow-Up Studies
- Humans
- Inflammatory Breast Neoplasms
(pathology, surgery)
- Lymph Node Excision
- Middle Aged
- Neoplasm Recurrence, Local
(pathology, surgery)
- Prognosis
- Prospective Studies
- Remission Induction
- Sentinel Lymph Node
(pathology, surgery)
- Young Adult
|